Skip to main content
SpringerLink
Log in

Acanthosis Nigricans

  • Chapter
  • First Online:
Endocrine Conditions in Pediatrics

  • 1189 Accesses

Abstract

Acanthosis nigricans (AN) is a common skin condition characterized by velvety hyperpigmented skin, most commonly noted in the intertriginous areas such as the neck and axillae. Clinical recognition of AN is essential because AN is associated with a variety of systemic and metabolic disorders, many of which are characterized by obesity and/or insulin resistance. Children with AN should be screened for diabetes and other comorbidities of obesity. Treatment involves addressing the underlying factors. Weight loss and improvement in insulin sensitivity may result in resolution of AN.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Pollitzer S. Acanthosis nigricans: a symptom of a disorder of the abdominal sympathetic. JAMA. 1909;53:1369–73.

    Article  Google Scholar 

  2. Sinha S, Schwartz RA. Juvenile acanthosis nigricans. J Am Acad Dermatol. 2007;57(3):502–8.

    Article  PubMed  Google Scholar 

  3. Robinson SS, Tasker S. Acanthosis nigricans juvenilis associated with obesity; report of a case, with observations on endocrine dysfunction in benign acanthosis nigricans. Arch Dermatol Syphilol. 1947;55(6):749–60.

    Article  CAS  Google Scholar 

  4. Jeong JS, Lee JY, Yoon TY. Unilateral nevoid acanthosis nigricans with a submammary location. Ann Dermatol. 2011;23(1):95–7.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Schwartz RA, Janniger CK. Childhood acanthosis nigricans. Cutis. 1995;55(6):337–41.

    CAS  PubMed  Google Scholar 

  6. Higgins SP, Freemark M, Prose NS. Acanthosis nigricans: a practical approach to evaluation and management. Dermatol Online J. 2008;14(9):2.

    Article  PubMed  Google Scholar 

  7. Berk DR, Spector EB, Bayliss SJ. Familial acanthosis nigricans due to K650T FGFR3 mutation. Arch Dermatol. 2007;143(9):1153–6.

    Article  CAS  PubMed  Google Scholar 

  8. Hirai H, et al. Acanthosis nigricans in a Japanese boy with hypochondroplasia due to a K650T mutation in FGFR3. Clin Pediatr Endocrinol. 2017;26(4):223–8.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Koyama S, et al. Transforming growth factor-alpha (TGF alpha)-producing gastric carcinoma with acanthosis nigricans: an endocrine effect of TGF alpha in the pathogenesis of cutaneous paraneoplastic syndrome and epithelial hyperplasia of the esophagus. J Gastroenterol. 1997;32(1):71–7.

    Article  CAS  PubMed  Google Scholar 

  10. Karadag AS, et al. Acanthosis nigricans and the metabolic syndrome. Clin Dermatol. 2018;36(1):48–53.

    Article  PubMed  Google Scholar 

  11. Rafalson L, Eysaman J, Quattrin T. Screening obese students for acanthosis nigricans and other diabetes risk factors in the urban school-based health center. Clin Pediatr (Phila). 2011;50(8):747–52.

    Article  Google Scholar 

  12. Hud JA Jr, et al. Prevalence and significance of acanthosis nigricans in an adult obese population. Arch Dermatol. 1992;128(7):941–4.

    Article  PubMed  Google Scholar 

  13. Friedman CI, Richards S, Kim MH. Familial acanthosis nigricans. A longitudinal study. J Reprod Med. 1987;32(7):531–6.

    CAS  PubMed  Google Scholar 

  14. Schmidt TH, et al. Cutaneous findings and systemic associations in women with polycystic ovary syndrome. JAMA Dermatol. 2016;152(4):391–8.

    Article  PubMed  Google Scholar 

  15. Jabbour SA. Cutaneous manifestations of endocrine disorders: a guide for dermatologists. Am J Clin Dermatol. 2003;4(5):315–31.

    Article  PubMed  Google Scholar 

  16. Schwartz RA. Acanthosis nigricans. J Am Acad Dermatol. 1994;31(1):1–19; quiz 20–2.

    Article  CAS  PubMed  Google Scholar 

  17. Arioglu E, et al. Clinical course of the syndrome of autoantibodies to the insulin receptor (type B insulin resistance): a 28-year perspective. Medicine (Baltimore). 2002;81(2):87–100.

    Article  CAS  Google Scholar 

  18. Baird JS, et al. Systemic lupus erythematosus with acanthosis nigricans, hyperpigmentation, and insulin receptor antibody. Lupus. 1997;6(3):275–8.

    Article  CAS  PubMed  Google Scholar 

  19. Torley D, Bellus GA, Munro CS. Genes, growth factors and acanthosis nigricans. Br J Dermatol. 2002;147(6):1096–101.

    Article  CAS  PubMed  Google Scholar 

  20. Munoz-Perez MA, Camacho F. Acanthosis nigricans: a new cutaneous sign in severe atopic dermatitis and Down syndrome. J Eur Acad Dermatol Venereol. 2001;15(4):325–7.

    CAS  PubMed  Google Scholar 

  21. Krawczyk M, Mykala-Ciesla J, Kolodziej-Jaskula A. Acanthosis nigricans as a paraneoplastic syndrome. Case reports and review of literature. Pol Arch Med Wewn. 2009;119(3):180–3.

    PubMed  Google Scholar 

  22. Pentenero M, et al. Oral acanthosis nigricans, tripe palms and sign of leser-trelat in a patient with gastric adenocarcinoma. Int J Dermatol. 2004;43(7):530–2.

    Article  CAS  PubMed  Google Scholar 

  23. Anderson SH, Hudson-Peacock M, Muller AF. Malignant acanthosis nigricans: potential role of chemotherapy. Br J Dermatol. 1999;141(4):714–6.

    Article  CAS  PubMed  Google Scholar 

  24. Skiljevic DS, et al. Generalized acanthosis nigricans in early childhood. Pediatr Dermatol. 2001;18(3):213–6.

    Article  CAS  PubMed  Google Scholar 

  25. Birns J, et al. Acanthosis nigricans associated with acute myeloid leukaemia. Eur J Intern Med. 2004;15(7):473.

    Article  CAS  PubMed  Google Scholar 

  26. Garrott TC. Malignant acanthosis nigricans associated with osteogenic sarcoma. Arch Dermatol. 1972;106(3):384–5.

    Article  CAS  PubMed  Google Scholar 

  27. Bhargava P, et al. Malignant acanthosis nigricans in a 2 year old child with Wilm’s Tumour. Indian J Dermatol Venereol Leprol. 1998;64(1):29–30.

    CAS  PubMed  Google Scholar 

  28. Stals H, et al. Acanthosis nigricans caused by nicotinic acid: case report and review of the literature. Dermatology. 1994;189(2):203–6.

    Article  CAS  PubMed  Google Scholar 

  29. Fleming MG, Simon SI. Cutaneous insulin reaction resembling acanthosis nigricans. Arch Dermatol. 1986;122(9):1054–6.

    Article  CAS  PubMed  Google Scholar 

  30. Skouby SO. Update on the metabolic effects of oral contraceptives. J Obstet Gynaecol (Lahore). 1986;6(Suppl 2):S104–9.

    Article  CAS  Google Scholar 

  31. Mellor-Pita S, et al. Acanthosis nigricans: a new manifestation of insulin resistance in patients receiving treatment with protease inhibitors. Clin Infect Dis. 2002;34(5):716–7.

    Article  PubMed  Google Scholar 

  32. Manu P, et al. Acanthosis nigricans during treatment with aripiprazole. Am J Ther. 2014;21(3):e90–3.

    Article  PubMed  Google Scholar 

  33. Krishnaram AS. Unilateral nevoid acanthosis nigricans. Int J Dermatol. 1991;30(6):452–3.

    Article  CAS  PubMed  Google Scholar 

  34. Schwartz RA. Acral acanthosis nigricans (acral acanthotic anomaly). J Am Acad Dermatol. 2007;56(2):349–50.

    Article  PubMed  Google Scholar 

  35. Arslanian S, et al. Evaluation and Management of Youth-Onset Type 2 diabetes: a position statement by the American Diabetes Association. Diabetes Care. 2018;41(12):2648–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Buse JB, et al. Diabetes screening with hemoglobin A(1c) versus fasting plasma glucose in a multiethnic middle-school cohort. Diabetes Care. 2013;36(2):429–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Chan WK, et al. Limited utility of plasma M30 in discriminating non-alcoholic steatohepatitis from steatosis--a comparison with routine biochemical markers. PLoS One. 2014;9(9):e105903.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  38. Kohli R, et al. Pediatric nonalcoholic fatty liver disease: a report from the expert committee on nonalcoholic fatty liver disease (ECON). J Pediatr. 2016;172:9–13.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Cook S, Kavey RE. Dyslipidemia and pediatric obesity. Pediatr Clin N Am. 2011;58(6):1363–73, ix.

    Article  Google Scholar 

  40. Expert Panel on Integrated Guidelines for Cardiovascular Health. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128(Suppl 5):S213–56.

    Google Scholar 

  41. Sharma A, et al. Diagnostic thresholds for androgen-producing tumors or pathologic hyperandrogenism in women by use of Total testosterone concentrations measured by liquid chromatography-tandem mass spectrometry. Clin Chem. 2018;64(11):1636–45.

    Article  CAS  PubMed  Google Scholar 

  42. Rosenfield RL, et al. Antimullerian hormone levels are independently related to ovarian hyperandrogenism and polycystic ovaries. Fertil Steril. 2012;98(1):242–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Elhassan YS, et al. Causes, patterns, and severity of androgen excess in 1205 consecutively recruited women. J Clin Endocrinol Metab. 2018;103(3):1214–23.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Lavery GG, et al. Steroid biomarkers and genetic studies reveal inactivating mutations in hexose-6-phosphate dehydrogenase in patients with cortisone reductase deficiency. J Clin Endocrinol Metab. 2008;93(10):3827–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Bellot-Rojas P, et al. Comparison of metformin versus rosiglitazone in patients with acanthosis nigricans: a pilot study. J Drugs Dermatol. 2006;5(9):884–9.

    PubMed  Google Scholar 

  46. Romo A, Benavides S. Treatment options in insulin resistance obesity-related acanthosis nigricans. Ann Pharmacother. 2008;42(7):1090–4.

    Article  CAS  PubMed  Google Scholar 

  47. Legro RS, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(12):4565–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Martin KA, et al. Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(4):1233–57.

    Article  PubMed  Google Scholar 

  49. Cremer M, Phan-Weston S, Jacobs A. Recent innovations in oral contraception. Semin Reprod Med. 2010;28(2):140–6.

    Article  PubMed  Google Scholar 

  50. Bagis T, et al. The effects of short-term medroxyprogesterone acetate and micronized progesterone on glucose metabolism and lipid profiles in patients with polycystic ovary syndrome: a prospective randomized study. J Clin Endocrinol Metab. 2002;87(10):4536–40.

    Article  CAS  PubMed  Google Scholar 

  51. Tercedor J, et al. Effect of ketoconazole in the hyperandrogenism, insulin resistance and acanthosis nigricans (HAIR-AN) syndrome. J Am Acad Dermatol. 1992;27(5 Pt 1):786.

    Article  CAS  PubMed  Google Scholar 

  52. Coates P, Shuttleworth D, Rees A. Resolution of nicotinic acid-induced acanthosis nigricans by substitution of an analogue (acipimox) in a patient with type V hyperlipidaemia. Br J Dermatol. 1992;126(4):412–4.

    Article  CAS  PubMed  Google Scholar 

  53. Lunetta M, et al. Long-term octreotide treatment reduced hyperinsulinemia, excess body weight and skin lesions in severe obesity with acanthosis nigricans. J Endocrinol Investig. 1996;19(10):699–703.

    Article  CAS  Google Scholar 

  54. Sherertz EF. Improved acanthosis nigricans with lipodystrophic diabetes during dietary fish oil supplementation. Arch Dermatol. 1988;124(7):1094–6.

    Article  CAS  PubMed  Google Scholar 

  55. Darmstadt GL, Yokel BK, Horn TD. Treatment of acanthosis nigricans with tretinoin. Arch Dermatol. 1991;127(8):1139–40.

    Article  CAS  PubMed  Google Scholar 

  56. Ichiyama S, et al. Effective treatment by glycolic acid peeling for cutaneous manifestation of familial generalized acanthosis nigricans caused by FGFR3 mutation. J Eur Acad Dermatol Venereol. 2016;30(3):442–5.

    Article  CAS  PubMed  Google Scholar 

  57. Rosenbach A, Ram R. Treatment of acanthosis nigricans of the axillae using a long-pulsed (5-msec) alexandrite laser. Dermatol Surg. 2004;30(8):1158–60.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology and Diabetes, Department of Pediatrics, UPMC Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA

    Mohamed Saleh & Radhika Muzumdar

  2. Division of Endocrinology and Diabetes, UPMC Children’s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

    Radhika Muzumdar

Authors
  1. Mohamed Saleh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Radhika Muzumdar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Radhika Muzumdar .

Editor information

Editors and Affiliations

  1. Division of Pediatric Endocrinology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

    Takara Stanley

  2. Division of Pediatric Endocrinology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

    Madhusmita Misra

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Saleh, M., Muzumdar, R. (2021). Acanthosis Nigricans. In: Stanley, T., Misra, M. (eds) Endocrine Conditions in Pediatrics. Springer, Cham. https://doi.org/10.1007/978-3-030-52215-5_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-52215-5_18

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-52214-8

  • Online ISBN: 978-3-030-52215-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation